• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MicroRNA-520a 通过靶向 RRM2/Wnt 轴抑制非小细胞肺癌的发病和进展。

MicroRNA-520a Suppresses Pathogenesis and Progression of Non-Small-Cell Lung Cancer through Targeting the RRM2/Wnt Axis.

机构信息

Department of Respiratory Oncology, Shandong Provincial Chest Hospital, Jinan, 250013 Shandong, China.

Department of Tuberculosis, Shandong Provincial Chest Hospital, Jinan, 250013 Shandong, China.

出版信息

Anal Cell Pathol (Amst). 2021 Mar 30;2021:9652420. doi: 10.1155/2021/9652420. eCollection 2021.

DOI:10.1155/2021/9652420
PMID:33859925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8026327/
Abstract

MicroRNAs (miRNAs) regulate multiple cellular behaviors, and their aberrant expression is frequently associated with disease progression. This research focused on the effects of miR-520a on the development of non-small-cell lung cancer (NSCLC) and the molecules involved. Tumor and normal tissues from 24 patients with NSCLC were collected. Differentially expressed miRNAs between tumor tissues and normal tissues were screened using microarrays, and miR-520a was screened to be significantly poorly expressed in tumor samples. Artificial upregulation of miR-520a reduced proliferation, migration and invasion, and resistance to death of NSCLC A549 and H460 cells according to the MTT, EdU labeling, transwell, and flow cytometry assays, respectively. miR-520a upregulation suppressed growth and metastasis of xenograft tumors in vivo. The integrated bioinformatic analysis and dual luciferase assays suggested that miR-520a targeted ribonucleotide reductase subunit 2 (RRM2) mRNA and inactivated the Wnt/-catenin signaling pathway in NSCLC cells. Upregulation of RRM2 enhanced the malignant behaviors of NSCLCs, but the oncogenic effects of RRM2 were blocked upon miR-520a overexpression. To conclude, this study evidenced that miR-520a inhibits NSCLC progression through suppressing RRM2 and the Wnt signaling pathway. This paper may offer novel insights into NSCLC treatment.

摘要

微小 RNA(miRNA)调节多种细胞行为,其异常表达常与疾病进展有关。本研究聚焦于 miR-520a 对非小细胞肺癌(NSCLC)发展的影响及其涉及的分子。收集了 24 例 NSCLC 患者的肿瘤和正常组织。通过微阵列筛选肿瘤组织和正常组织之间差异表达的 miRNA,筛选出 miR-520a 在肿瘤样本中表达明显下调。MTT、EdU 标记、Transwell 和流式细胞术分别证实,人工上调 miR-520a 可降低 NSCLC A549 和 H460 细胞的增殖、迁移和侵袭能力,并提高其对死亡的抵抗能力。miR-520a 的上调抑制了体内异种移植肿瘤的生长和转移。整合的生物信息学分析和双荧光素酶报告基因实验表明,miR-520a 靶向核糖核苷酸还原酶亚基 2(RRM2)mRNA,并在 NSCLC 细胞中失活 Wnt/-连环蛋白信号通路。RRM2 的上调增强了 NSCLC 的恶性行为,但 miR-520a 过表达阻断了 RRM2 的致癌作用。总之,本研究证明 miR-520a 通过抑制 RRM2 和 Wnt 信号通路抑制 NSCLC 的进展。本文可能为 NSCLC 的治疗提供新的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/965c58ff0533/ACP2021-9652420.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/160d170fd9f6/ACP2021-9652420.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/af5790e6b228/ACP2021-9652420.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/ff05d77f6a56/ACP2021-9652420.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/be33495038f5/ACP2021-9652420.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/965c58ff0533/ACP2021-9652420.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/160d170fd9f6/ACP2021-9652420.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/af5790e6b228/ACP2021-9652420.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/ff05d77f6a56/ACP2021-9652420.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/be33495038f5/ACP2021-9652420.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d2b/8026327/965c58ff0533/ACP2021-9652420.005.jpg

相似文献

1
MicroRNA-520a Suppresses Pathogenesis and Progression of Non-Small-Cell Lung Cancer through Targeting the RRM2/Wnt Axis.MicroRNA-520a 通过靶向 RRM2/Wnt 轴抑制非小细胞肺癌的发病和进展。
Anal Cell Pathol (Amst). 2021 Mar 30;2021:9652420. doi: 10.1155/2021/9652420. eCollection 2021.
2
MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.miRNA-20a-5p 通过 RRM2 介导的 PI3K/Akt 信号通路抑制非小细胞肺癌的肿瘤血管生成。
Mol Cell Biochem. 2021 Feb;476(2):689-698. doi: 10.1007/s11010-020-03936-y. Epub 2020 Oct 30.
3
LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.长链非编码 RNA SNHG16 通过海绵吸附 miR-520a-3p 调控 EphA2 表达促进非小细胞肺癌发展。
Thorac Cancer. 2020 Mar;11(3):603-611. doi: 10.1111/1759-7714.13304. Epub 2020 Jan 17.
4
Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway.上调的长链非编码RNA SNHG1通过抑制miR-101-3p和激活Wnt/β-连环蛋白信号通路促进非小细胞肺癌进展。
Oncotarget. 2017 Mar 14;8(11):17785-17794. doi: 10.18632/oncotarget.14854.
5
Long noncoding RNA HOXA-AS2 promotes non-small cell lung cancer progression by regulating miR-520a-3p.长链非编码 RNA HOXA-AS2 通过调控 miR-520a-3p 促进非小细胞肺癌进展。
Biosci Rep. 2019 May 31;39(5). doi: 10.1042/BSR20190283.
6
Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt/β-catenin signaling in non-small-cell lung cancer.下调 miR-3127-5p 通过 FZD4 调控 Wnt/β-catenin 信号通路促进非小细胞肺癌上皮-间质转化。
Mol Carcinog. 2018 Jul;57(7):842-853. doi: 10.1002/mc.22805. Epub 2018 Apr 14.
7
microRNA-100 functions as a tumor suppressor in non-small cell lung cancer via regulating epithelial-mesenchymal transition and Wnt/β-catenin by targeting HOXA1.miRNA-100 通过靶向 HOXA1 调控上皮-间充质转化和 Wnt/β-catenin 通路发挥抑癌作用在非小细胞肺癌中
Thorac Cancer. 2020 Jun;11(6):1679-1688. doi: 10.1111/1759-7714.13459. Epub 2020 May 4.
8
MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.miR-770 通过靶向 JMJD6 并调控非小细胞肺癌中的 WNT/β-catenin 通路抑制肿瘤发生和 EMT。
Life Sci. 2017 Nov 1;188:163-171. doi: 10.1016/j.lfs.2017.09.002. Epub 2017 Sep 4.
9
Upregulation of long intergenic non-coding RNA LINC00326 inhibits non-small cell lung carcinoma progression by blocking Wnt/β-catenin pathway through modulating the miR-657/dickkopf WNT signaling pathway inhibitor 2 axis.长链非编码 RNA LINC00326 的上调通过调节 miR-657/ Dickkopf WNT 信号通路抑制剂 2 轴来阻断 Wnt/β-连环蛋白通路抑制非小细胞肺癌的进展。
Biol Direct. 2023 Feb 6;18(1):3. doi: 10.1186/s13062-023-00359-9.
10
MicroRNA-582-3p targeting ribonucleotide reductase regulatory subunit M2 inhibits the tumorigenesis of hepatocellular carcinoma by regulating the Wnt/β-catenin signaling pathway.miRNA-582-3p 通过靶向核苷酸还原酶调节亚基 M2 抑制 Wnt/β-catenin 信号通路抑制肝癌的发生发展。
Bioengineered. 2022 May;13(5):12876-12887. doi: 10.1080/21655979.2022.2078026.

引用本文的文献

1
Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer.Wnt/β-catenin 信号通路在非小细胞肺癌发生发展及治疗抵抗中的作用
J Transl Med. 2024 Jun 13;22(1):565. doi: 10.1186/s12967-024-05380-8.
2
Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer.微小RNA对非小细胞肺癌的调控作用及治疗潜力
Heliyon. 2023 Nov 14;9(11):e22080. doi: 10.1016/j.heliyon.2023.e22080. eCollection 2023 Nov.
3
Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer.

本文引用的文献

1
Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with Propofol via miR-520a-3p/LIMK1 axis.外泌体长链非编码 RNA H19 通过 miR-520a-3p/LIMK1 轴促进丙泊酚治疗的肝细胞癌的进展。
Cancer Med. 2020 Oct;9(19):7218-7230. doi: 10.1002/cam4.3313. Epub 2020 Aug 7.
2
Ropivacaine Inhibits the Growth, Migration and Invasion of Gastric Cancer Through Attenuation of WEE1 and PI3K/AKT Signaling via miR-520a-3p.罗哌卡因通过miR-520a-3p减弱WEE1和PI3K/AKT信号通路来抑制胃癌的生长、迁移和侵袭。
Onco Targets Ther. 2020 Jun 9;13:5309-5321. doi: 10.2147/OTT.S244550. eCollection 2020.
3
Long noncoding RNA SOX21-AS1 regulates the progression of triple-negative breast cancer through regulation of miR-520a-5p/ORMDL3 axis.
核苷酸还原酶调节亚基 M2(RRM2)作为非小细胞肺癌潜在的血清学诊断生物标志物。
PLoS One. 2023 Sep 12;18(9):e0291461. doi: 10.1371/journal.pone.0291461. eCollection 2023.
4
HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas.HELLPAR/RRM2 轴与 HMMR 作为胶质瘤的新型预后生物标志物相关。
BMC Cancer. 2023 Feb 7;23(1):125. doi: 10.1186/s12885-023-10596-w.
5
The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer.免疫系统和分子细胞信号通路在肺癌发病机制和进展中的重要性。
Int J Mol Sci. 2023 Jan 12;24(2):1506. doi: 10.3390/ijms24021506.
6
The potential of miR-153 as aggressive prostate cancer biomarker.miR-153作为侵袭性前列腺癌生物标志物的潜力。
Noncoding RNA Res. 2022 Oct 13;8(1):53-59. doi: 10.1016/j.ncrna.2022.10.002. eCollection 2023 Mar.
7
miR-29a-3p inhibits the malignant characteristics of non-small cell lung cancer cells by reducing the activity of the Wnt/β-catenin signaling pathway.微小RNA-29a-3p通过降低Wnt/β-连环蛋白信号通路的活性来抑制非小细胞肺癌细胞的恶性特征。
Oncol Lett. 2022 Sep 12;24(4):379. doi: 10.3892/ol.2022.13499. eCollection 2022 Oct.
8
Circ_0039908/miR-let-7c/RRM2 axis was identified played an important role in lung adenocarcinoma by integrated analysis.通过综合分析发现,Circ_0039908/miR-let-7c/RRM2轴在肺腺癌中起重要作用。
J Cancer. 2022 Jul 18;13(10):2988-2999. doi: 10.7150/jca.72789. eCollection 2022.
9
MicroRNA-582-3p targeting ribonucleotide reductase regulatory subunit M2 inhibits the tumorigenesis of hepatocellular carcinoma by regulating the Wnt/β-catenin signaling pathway.miRNA-582-3p 通过靶向核苷酸还原酶调节亚基 M2 抑制 Wnt/β-catenin 信号通路抑制肝癌的发生发展。
Bioengineered. 2022 May;13(5):12876-12887. doi: 10.1080/21655979.2022.2078026.
10
High RRM2 expression has poor prognosis in specific types of breast cancer.高 RRM2 表达预示着某些特定类型乳腺癌的不良预后。
PLoS One. 2022 Mar 15;17(3):e0265195. doi: 10.1371/journal.pone.0265195. eCollection 2022.
长链非编码 RNA SOX21-AS1 通过调控 miR-520a-5p/ORMDL3 轴调控三阴性乳腺癌的进展。
J Cell Biochem. 2020 Nov;121(11):4601-4611. doi: 10.1002/jcb.29674. Epub 2020 Apr 10.
4
The lncRNA NORAD/miR-520a-3p Facilitates Malignancy in Non-Small Cell Lung Cancer via PI3k/Akt/mTOR Signaling Pathway.长链非编码RNA NORAD/微小RNA-520a-3p通过PI3k/Akt/mTOR信号通路促进非小细胞肺癌的恶性进展。
Onco Targets Ther. 2020 Feb 19;13:1533-1544. doi: 10.2147/OTT.S230954. eCollection 2020.
5
New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.晚期非小细胞肺癌抗血管生成联合治疗策略的新进展。
J Cancer Res Clin Oncol. 2020 Mar;146(3):631-645. doi: 10.1007/s00432-020-03129-6. Epub 2020 Feb 17.
6
LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.长链非编码 RNA SNHG16 通过海绵吸附 miR-520a-3p 调控 EphA2 表达促进非小细胞肺癌发展。
Thorac Cancer. 2020 Mar;11(3):603-611. doi: 10.1111/1759-7714.13304. Epub 2020 Jan 17.
7
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
8
RRM2 Regulated By LINC00667/miR-143-3p Signal Is Responsible For Non-Small Cell Lung Cancer Cell Progression.由LINC00667/miR-143-3p信号调控的RRM2负责非小细胞肺癌细胞的进展。
Onco Targets Ther. 2019 Nov 20;12:9927-9939. doi: 10.2147/OTT.S221339. eCollection 2019.
9
LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2.长链非编码RNA AFAP1-AS1通过竞争性上调RRM2抑制miR-139-5p并促进非小细胞肺癌的细胞增殖和化疗耐药性。
Front Oncol. 2019 Oct 22;9:1103. doi: 10.3389/fonc.2019.01103. eCollection 2019.
10
Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.靶向癌症生物学和治疗中的多功能 Wnt/β-连环蛋白通路:从概念到可行的策略。
OMICS. 2019 Nov;23(11):517-538. doi: 10.1089/omi.2019.0147. Epub 2019 Oct 15.